Abiraterone（154229-19-3）

Overview: Abiteron is a targeted cytochrome CYP17 (17 α- Hydroxylase/C17,20-lyase) inhibitor, which is hydrolyzed to produce abiolone, and abiolone acetate can reduce the production of testosterone by inhibiting CYP17, which is suitable for the treatment of patients who have previously received chemotherapy containing docetaxel to transfer castrated refractory prostate cancer (CRP C). Clinical trials have proved that the combination of Abiteron and prednisone can significantly prolong the total survival period of patients with metastatic prostate cancer who have previously received docetaxel chemotherapy. Follow-up studies found that Abitren also had significant effect on patients who had not received docetaxel chemotherapy, and according to this, Abitren was listed as the first-line treatment of metastatic CRP in the guidelines. The latest research shows that abiolone can benefit patients with locally advanced or metastatic prostate cancer. These results will promote abiolone to enter the first-line treatment of advanced prostate cancer early.